Reports
Sale
Global Genitourinary Drugs Market Share, Size, Analysis, Growth: By Indication: Ovarian Cancer, Prostate Cancer, Bladder Cancer, Cervical Cancer, Erectile Dysfunction, Sexually Transmitted Diseases, Interstitial Cystitis, Benign Prostatic Hyperplasia, Others; By Product: Urologicals, Others; Regional Analysis; Competitive Landscape; 2023-2028
Global Genitourinary Drugs Market Outlook
The global genitourinary drugs market is expected to grow at a CAGR of 3.30% in the forecast period of between 2023 and 2028, driven by the prevalence of genitourinary conditions, STDs, and cancer.
Key Trends in the Market
The genitourinary system comprises of the kidneys, ureter, bladder, urethra, and genital organs which are crucial for reproduction and eliminating waste from the body. The system’s functionality can be impaired by congenital anomalies, infections, iatrogenic injuries, hydronephrosis, cancer, trauma, and inflammation. Globally, there is a surge in demand for genitourinary medications as a result of the increasing number of people who have these conditions. Genitourinary medications are prescribed to treat disorders of the urinary tract, reproductive organs, and excretory system.
- The genitourinary drugs market worldwide is anticipated to grow throughout the forecast period. One of the main factors propelling the market for genitourinary drugs is the increasing prevalence of genitourinary conditions like erectile dysfunction, ovarian cancer, sexually transmitted diseases, bladder cancer, and benign prostatic hyperplasia.
- The leading companies in the market are concentrating on developing medication formulations that assist in treating patients with persistent prostate cancer who have grown resistant to standard chemotherapeutic and hormone treatment agents.
- A number of multinational corporations are working with top biopharmaceutical companies to introduce next-generation treatments and boost their market share. This is helping in the genitourinary drugs market expansion, facilitating a notable increase in the number of pipeline medications that are currently undergoing late-stage clinical studies.
- Further, it is expected that the demand for genitourinary medications would increase in the approaching years due to rising financing for research and development initiatives and advancements in the healthcare infrastructure supported by governmental and non- governmental bodies of many countries.
Global Genitourinary Drugs Market Analysis
Based on indication, the market is divided into ovarian cancer, prostate cancer, bladder cancer, cervical cancer, erectile dysfunction, sexually transmitted diseases, interstitial cystitis, and benign prostatic hyperplasia, among others. The market on the basis of product is segmented into urologicals, hormonal therapy drugs, anti-infectives, and gynaecological, among others. The regional markets for genitourinary drugs can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global genitourinary drugs market, covering their competitive landscape and latest developments like mergers, acquisitions, investments, and expansion plans.
- Bristol-Myers Squibb Company
- Novartis AG
- F. Hoffmann-La Roche Ltd
- Genentech, Inc.
- Pfizer Inc.
- Others
Market Share by Indication
Prostate cancer is anticipated to account for a leading share of the market for genitourinary drugs. This can be attributed to its wide prevalence, and the vast spectrum of treatments used to treat prostate cancer, including immunotherapy drugs, radiopharmaceuticals, and anti-neoplastic medicines.
The major causes of prostate cancer include an ageing population, obesity, diet, and family history. The genitourinary drugs market supports improved survival rates, slowed disease progression, and minimal side effects. Furthermore, it is projected that invasive operations won't be necessary in the future due to the developments in formulation techniques and next-generation therapies.
Market Share by Region
The genitourinary drugs market growth is predicted to be dominated by North America because of the region's expanding health care infrastructure, rising awareness of genitourinary problems, and rising need for better therapies and treatments for genitourinary diseases. During the course of the forecast period, the market expansion is anticipated to be fuelled by the rising prevalence of erectile dysfunction or ED in the United States.
During the projected period, the Asia Pacific market for genitourinary drugs is anticipated to expand at a profitable rate, fuelled by rising awareness in economies like China and India. The significant investments in research and development by major players and persistent efforts to market branded treatments at affordable prices are the driving forces for the market in the region. Rising disposable income will further increases the likelihood of using branded drugs, and ongoing improvements in healthcare infrastructure are also expected to support the market growth in the Asia Pacific.
Competitive Landscape
Bristol-Myers Squibb Company, a multinational biopharmaceutical firm with headquarters in New York in the United States researches, develops, and distributes cutting-edge medications that aid patients in overcoming life-threatening illnesses. As part of its dedication to patient care, Bristol Myers Squibb works tirelessly to improve the quality of life for cancer patients as well as to define the future of cancer treatment. The business is renowned for its work in biological and pharmaceutical research.
Novartis AG, a Swiss corporation, is among the biggest producers of medications worldwide. Two significant Swiss pharmaceutical firms, Ciba-Geigy AG and Sandoz AG, combined to form Novartis in 1997. It offers medications for the treatment of infections, immunological disorders, ophthalmic and respiratory illnesses, cancer, cardiovascular diseases, dermatological issues, neurological disorders, and cancer.
F. Hoffmann-La Roche Ltd, a biotechnology business, with headquarters in Switzerland, creates medications and diagnostics to treat serious illnesses. It offers medications to treat conditions like cancer, autoimmune diseases, issues with central nervous systems, eye and vision problems, infectious diseases, and respiratory illnesses. Roche conducts research to find fresh approaches to preventing, diagnosing, and treating illnesses.
Other market players include Genentech, Inc. and Pfizer Inc., among others.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2018-2022 |
| Forecast Period | 2023-2028 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Indication |
|
| Breakup by Product |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Genitourinary Drugs Market Analysis
8.1 Key Industry Highlights
8.2 Global Genitourinary Drugs Historical Market (2018-2022)
8.3 Global Genitourinary Drugs Market Forecast (2023-2028)
8.4 Global Genitourinary Drugs Market by Indication
8.4.1 Ovarian Cancer
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2022)
8.4.1.3 Forecast Trend (2023-2028)
8.4.2 Prostate Cancer
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2022)
8.4.2.3 Forecast Trend (2023-2028)
8.4.3 Bladder Cancer
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2018-2022)
8.4.3.3 Forecast Trend (2023-2028)
8.4.4 Cervical Cancer
8.4.4.1 Market Share
8.4.4.2 Historical Trend (2018-2022)
8.4.4.3 Forecast Trend (2023-2028)
8.4.5 Erectile Dysfunction
8.4.5.1 Market Share
8.4.5.2 Historical Trend (2018-2022)
8.4.5.3 Forecast Trend (2023-2028)
8.4.6 Sexually Transmitted Diseases
8.4.6.1 Market Share
8.4.6.2 Historical Trend (2018-2022)
8.4.6.3 Forecast Trend (2023-2028)
8.4.7 Interstitial Cystitis
8.4.7.1 Market Share
8.4.7.2 Historical Trend (2018-2022)
8.4.7.3 Forecast Trend (2023-2028)
8.4.8 Benign Prostatic Hyperplasia
8.4.8.1 Market Share
8.4.8.2 Historical Trend (2018-2022)
8.4.8.3 Forecast Trend (2023-2028)
8.4.9 Others
8.5 Global Genitourinary Drugs Market by Product
8.5.1 Urologicals
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2018-2022)
8.5.1.3 Forecast Trend (2023-2028)
8.5.2 Hormonal Therapy Drugs
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2018-2022)
8.5.2.3 Forecast Trend (2023-2028)
8.5.3 Anti-infectives
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2018-2022)
8.5.3.3 Forecast Trend (2023-2028)
8.5.4 Gynaecological
8.5.4.1 Market Share
8.5.4.2 Historical Trend (2018-2022)
8.5.4.3 Forecast Trend (2023-2028)
8.5.5 Others
8.6 Global Genitourinary Drugs Market by Region
8.6.1 North America
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2018-2022)
8.6.1.3 Forecast Trend (2023-2028)
8.6.2 Europe
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2018-2022)
8.6.2.3 Forecast Trend (2023-2028)
8.6.3 Asia Pacific
8.6.3.1 Market Share
8.6.3.2 Historical Trend (2018-2022)
8.6.3.3 Forecast Trend (2023-2028)
8.6.4 Latin America
8.6.4.1 Market Share
8.6.4.2 Historical Trend (2018-2022)
8.6.4.3 Forecast Trend (2023-2028)
8.6.5 Middle East and Africa
8.6.5.1 Market Share
8.6.5.2 Historical Trend (2018-2022)
8.6.5.3 Forecast Trend (2023-2028)
9 North America Genitourinary Drugs Market Analysis
9.1 United States of America
9.1.1 Market Share
9.1.2 Historical Trend (2018-2022)
9.1.3 Forecast Trend (2023-2028)
9.2 Canada
9.2.1 Market Share
9.2.2 Historical Trend (2018-2022)
9.2.3 Forecast Trend (2023-2028)
10 Europe Genitourinary Drugs Market Analysis
10.1 United Kingdom
10.1.1 Market Share
10.1.2 Historical Trend (2018-2022)
10.1.3 Forecast Trend (2023-2028)
10.2 Germany
10.2.1 Market Share
10.2.2 Historical Trend (2018-2022)
10.2.3 Forecast Trend (2023-2028)
10.3 France
10.3.1 Market Share
10.3.2 Historical Trend (2018-2022)
10.3.3 Forecast Trend (2023-2028)
10.4 Italy
10.4.1 Market Share
10.4.2 Historical Trend (2018-2022)
10.4.3 Forecast Trend (2023-2028)
10.5 Others
11 Asia Pacific Genitourinary Drugs Market Analysis
11.1 China
11.1.1 Market Share
11.1.2 Historical Trend (2018-2022)
11.1.3 Forecast Trend (2023-2028)
11.2 Japan
11.2.1 Market Share
11.2.2 Historical Trend (2018-2022)
11.2.3 Forecast Trend (2023-2028)
11.3 India
11.3.1 Market Share
11.3.2 Historical Trend (2018-2022)
11.3.3 Forecast Trend (2023-2028)
11.4 ASEAN
11.4.1 Market Share
11.4.2 Historical Trend (2018-2022)
11.4.3 Forecast Trend (2023-2028)
11.5 Australia
11.5.1 Market Share
11.5.2 Historical Trend (2018-2022)
11.5.3 Forecast Trend (2023-2028)
11.6 Others
12 Latin America Genitourinary Drugs Market Analysis
12.1 Brazil
12.1.1 Market Share
12.1.2 Historical Trend (2018-2022)
12.1.3 Forecast Trend (2023-2028)
12.2 Argentina
12.2.1 Market Share
12.2.2 Historical Trend (2018-2022)
12.2.3 Forecast Trend (2023-2028)
12.3 Mexico
12.3.1 Market Share
12.3.2 Historical Trend (2018-2022)
12.3.3 Forecast Trend (2023-2028)
12.4 Others
13 Middle East and Africa Genitourinary Drugs Market Analysis
13.1 Saudi Arabia
13.1.1 Market Share
13.1.2 Historical Trend (2018-2022)
13.1.3 Forecast Trend (2023-2028)
13.2 United Arab Emirates
13.2.1 Market Share
13.2.2 Historical Trend (2018-2022)
13.2.3 Forecast Trend (2023-2028)
13.3 Nigeria
13.3.1 Market Share
13.3.2 Historical Trend (2018-2022)
13.3.3 Forecast Trend (2023-2028)
13.4 South Africa
13.4.1 Market Share
13.4.2 Historical Trend (2018-2022)
13.4.3 Forecast Trend (2023-2028)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Competitive Landscape
15.1 Market Structure
15.2 Company Profiles
15.2.1 Bristol-Myers Squibb Company
15.2.1.1 Company Overview
15.2.1.2 Product Portfolio
15.2.1.3 Demographic Reach and Achievements
15.2.1.4 Certifications
15.2.2 Novartis AG
15.2.2.1 Company Overview
15.2.2.2 Product Portfolio
15.2.2.3 Demographic Reach and Achievements
15.2.2.4 Certifications
15.2.3 F. Hoffmann-La Roche Ltd
15.2.3.1 Company Overview
15.2.3.2 Product Portfolio
15.2.3.3 Demographic Reach and Achievements
15.2.3.4 Certifications
15.2.4 Genentech, Inc.
15.2.4.1 Company Overview
15.2.4.2 Product Portfolio
15.2.4.3 Demographic Reach and Achievements
15.2.4.4 Certifications
15.2.5 Pfizer Inc.
15.2.5.1 Company Overview
15.2.5.2 Product Portfolio
15.2.5.3 Demographic Reach and Achievements
15.2.5.4 Certifications
15.2.6 Others
16 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Genitourinary Drugs Market: Key Industry Highlights, 2018 and 2028
2. Global Genitourinary Drugs Historical Market: Breakup by Indication (USD Million), 2018-2022
3. Global Genitourinary Drugs Market Forecast: Breakup by Indication (USD Million), 2023-2028
4. Global Genitourinary Drugs Historical Market: Breakup by Product (USD Million), 2018-2022
5. Global Genitourinary Drugs Market Forecast: Breakup by Product (USD Million), 2023-2028
6. Global Genitourinary Drugs Historical Market: Breakup by Region (USD Million), 2018-2022
7. Global Genitourinary Drugs Market Forecast: Breakup by Region (USD Million), 2023-2028
8. North America Genitourinary Drugs Historical Market: Breakup by Country (USD Million), 2018-2022
9. North America Genitourinary Drugs Market Forecast: Breakup by Country (USD Million), 2023-2028
10. Europe Genitourinary Drugs Historical Market: Breakup by Country (USD Million), 2018-2022
11. Europe Genitourinary Drugs Market Forecast: Breakup by Country (USD Million), 2023-2028
12. Asia Pacific Genitourinary Drugs Historical Market: Breakup by Country (USD Million), 2018-2022
13. Asia Pacific Genitourinary Drugs Market Forecast: Breakup by Country (USD Million), 2023-2028
14. Latin America Genitourinary Drugs Historical Market: Breakup by Country (USD Million), 2018-2022
15. Latin America Genitourinary Drugs Market Forecast: Breakup by Country (USD Million), 2023-2028
16. Middle East and Africa Genitourinary Drugs Historical Market: Breakup by Country (USD Million), 2018-2022
17. Middle East and Africa Genitourinary Drugs Market Forecast: Breakup by Country (USD Million), 2023-2028
18. Global Genitourinary Drugs Market Structure
Key Questions Answered in the Report
The market is projected to grow at a CAGR of 3.30% between 2023 and 2028.
The major drivers of the genitourinary drugs market include rising frequency of genitourinary illnesses, improvements in the healthcare infrastructure, and increasing awareness about genitourinary disorders.
Increasing funding for research and development, rise in the number of pipeline drugs in late-stage clinical trials, and launch of next-generation therapeutics are the key industry trends propelling the growth of the market.
The major players in the industry are Bristol-Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche Ltd, Genentech, Inc., and Pfizer Inc., among others.
Genitourinary drugs are used to treat infections to the genitourinary tract, congenital abnormalities, trauma, cancer, inflammation, iatrogenic injuries, and other ailments that cause damage to genitourinary organs.
The various genitourinary drug products are urologicals, hormonal therapy drugs, anti-infectives, and gynaecological, among others.
All organs involved in reproduction as well as those involved in urine production and excretion make up the genitourinary system, for example, fallopian tubes, kidneys, prostate, and bladder.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 2199
$1799
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$3199$2999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$4199$3999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$5199$4999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER